跨性别激素治疗中内脏脂肪与总体脂变化及其对心血管代谢风险因素的影响
研究纳入179名跨性别女性和162名跨性别男性,通过双能X射线吸收法评估激素治疗1年前后总体脂和内脏脂肪变化,并分析其与血脂和胰岛素抵抗的关系。结果显示跨性别女性总体脂增加但内脏脂肪未变,VAT/TBF比值下降;跨性别男性总体脂减少但内脏脂肪未变,VAT/TBF比值上升。VAT/TBF变化与血脂或HOMA-IR变化无关,提示激素治疗对心血管代谢的不利影响并非由内脏脂肪或VAT/TBF变化介导。
要点
- 跨性别女性激素治疗1年后总体脂增加4.0 kg,内脏脂肪未变,VAT/TBF比值下降17%。
- 跨性别男性激素治疗1年后总体脂减少2.8 kg,内脏脂肪未变,VAT/TBF比值上升14%。
- VAT/TBF变化与血脂或HOMA-IR变化无关。
核心结论
- 跨性别女性和男性的激素治疗导致VAT/TBF变化,主要归因于总体脂变化,且与心血管代谢风险因素变化无关。
- 激素治疗对心血管代谢的不利影响并非由内脏脂肪或VAT/TBF变化介导。
研究设计与样本
- 前瞻性队列研究,纳入179名跨性别女性和162名跨性别男性,在激素治疗前和1年后使用双能X射线吸收法估计总体脂和内脏脂肪。
- 采用线性回归分析VAT/TBF变化与血脂及胰岛素抵抗(HOMA-IR)变化的关系。
主要发现
- 跨性别女性总体脂增加4.0 kg(95% CI 3.4, 4.7),内脏脂肪变化-2克(95% CI -15, 11),范围-318至281,VAT/TBF比值下降17%(95% CI 15, 19)。
- 跨性别男性总体脂减少2.8 kg(95% CI 2.2, 3.5),内脏脂肪变化3克(95% CI -10, 16),范围-372至311,VAT/TBF比值上升14%(95% CI 10, 17)。
- 两组中VAT/TBF与血脂或HOMA-IR变化均无关联。
临床怎么用
- 跨性别个体激素治疗期间应监测体脂分布变化,但内脏脂肪或VAT/TBF变化可能不是心血管代谢风险的主要驱动因素。
- 临床关注激素治疗对心血管代谢的影响时,需综合考虑其他机制而非仅依赖内脏脂肪评估。
局限性
- 研究为观察性设计,无法确定因果关系。
- 内脏脂肪通过双能X射线吸收法估算,可能存在测量误差。
- 未报告样本的详细基线特征和激素治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Excess visceral fat increases the risk of type 2 diabetes and cardiovascular disease and is influenced by sex hormones. Our aim was to investigate changes in visceral fat and the ratio of visceral fat to total body fat (VAT/TBF) and their associations with changes in lipids and insulin resistance after 1 year of hormone therapy in trans persons. METHODS: In 179 trans women and 162 trans men, changes in total body and visceral fat estimated with dual-energy X-ray absorptiometry before and after 1 year of hormone therapy were related to lipids and insulin resistance [homeostatic model assessment of insulin resistance (HOMA-IR)] with linear regression analysis. RESULTS: In trans women, total body fat increased by 4.0 kg (95% CI 3.4, 4.7), while the amount of visceral fat did not change (-2 grams; 95% CI -15, 11), albeit with a large range from -318 to 281, resulting in a decrease in the VAT/TBF ratio of 17% (95% CI 15, 19). In trans men, total body fat decreased with 2.8 kg (95% CI 2.2, 3.5), while the amount of visceral fat did not change (3 g; 95% CI -10, 16; range -372, 311), increasing the VAT/TBF ratio by 14% (95% CI 10, 17). In both groups, VAT/TBF was not associated with changes in blood lipids or HOMA-IR. CONCLUSIONS: Hormone therapy in trans women and trans men resulted in changes in VAT/TBF, mainly due to changes in total body fat and were unrelated to changes in cardiometabolic risk factors, which suggests that any unfavorable cardiometabolic effects of hormone therapy are not mediated by changes in visceral fat or VAT/TBF.
引用
- Klaver M, van Velzen D, de Blok C, et al. Change in Visceral Fat and Total Body Fat and the Effect on Cardiometabolic Risk Factors During Transgender Hormone Therapy. J Clin Endocrinol Metab. 2022. PMID: 34415999. doi:10.1210/clinem/dgab616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。